4.8 Article

Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers

期刊

SCIENCE TRANSLATIONAL MEDICINE
卷 13, 期 624, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.abl4097

关键词

-

资金

  1. NIH [HL134539, AI155171, AI116228, AI078799, DA047034, AI150396, R37 AI067073]
  2. Bill and Melinda Gates Foundation [INV-002703, AI114235, AI117841, AI120008, AI130005, DK120387, AI152979, AI135940, AI155233, OPP1066973]
  3. American Foundation for AIDS Research (amfAR) [110181]
  4. DARE Collaboratory [UM1AI126611]
  5. BEAT-HIV Martin Delaney Collaboratory [UM1 AI126620]
  6. Consejo Superior de Investigaciones Cientificas (CSIC)
  7. Instituto de Salud Carlos III [PI19/01127]
  8. Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades Junta de Andalucia [P20_01276]
  9. Delaney AIDS Research Enterprise (DARE) [AI096109, A127966]
  10. amfAR Institute for HIV Cure Research [amfAR 109301]
  11. Ragon Institute of MGH, MIT and Harvard
  12. Mark and Lisa Schwartz Family Foundation
  13. Frederick National Laboratory for Cancer Research [HHSN261200800001E]
  14. Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research
  15. Harvard University - U.S. National Institutes of Health: NIAID [P30 AI060354]
  16. Harvard University - U.S. National Institutes of Health: NCI [P30 AI060354]
  17. Harvard University - U.S. National Institutes of Health: NICHD [P30 AI060354]
  18. Harvard University - U.S. National Institutes of Health: NHLBI [P30 AI060354]
  19. Harvard University - U.S. National Institutes of Health: NIDA [P30 AI060354]
  20. Harvard University - U.S. National Institutes of Health: NIMH [P30 AI060354]
  21. Harvard University - U.S. National Institutes of Health: NIA [P30 AI060354]
  22. Harvard University - U.S. National Institutes of Health: FIC [P30 AI060354]
  23. Harvard University - U.S. National Institutes of Health: OAR [P30 AI060354]
  24. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NIAID [P30 AI027763]
  25. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NCI [P30 AI027763]
  26. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NICHD [P30 AI027763]
  27. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NHLBI [P30 AI027763]
  28. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NIDA [P30 AI027763]
  29. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NIMH [P30 AI027763]
  30. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: NIA [P30 AI027763]
  31. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: FIC [P30 AI027763]
  32. University of California at San Francisco (UCSF)/Gladstone Institute for HIV Cure Research Centers for AIDS Research - U.S. National Institutes of Health: OAR [P30 AI027763]
  33. Fondos FEDER
  34. Bill and Melinda Gates Foundation [INV-002703] Funding Source: Bill and Melinda Gates Foundation

向作者/读者索取更多资源

The study found that defective proviruses in elite controllers are more commonly located in permissive genic euchromatin positions, while intact proviruses are frequently found in heterochromatin regions, indicating differential immune selection pressure on intact and defective proviruses in ECs. The intact and defective proviruses from ECs also showed reduced frequencies of escape mutations in key immune response regions, possibly due to the small and poorly inducible reservoir in ECs. Additionally, a subset of ECs harbored nef deletions in intact proviruses, which may increase viral vulnerability to host immunity in these individuals.
Increasing evidence suggests that durable drug-free control of HIV-1 replication is enabled by effective cellular immune responses that may induce an attenuated viral reservoir configuration with a weaker ability to drive viral rebound. Here, we comprehensively tracked effects of antiviral immune responses on intact and defective proviral sequences from elite controllers (ECs), analyzing both classical escape mutations and HIV-1 chromosomal integration sites as biomarkers of antiviral immune selection pressure. We observed that, within ECs, defective proviruses were commonly located in permissive genic euchromatin positions, which represented an apparent contrast to autologous intact proviruses that were frequently located in heterochromatin regions; this suggests differential immune selection pressure on intact versus defective proviruses in ECs. In comparison to individuals receiving antiretroviral therapy, intact and defective proviruses from ECs showed reduced frequencies of escape mutations in cytotoxic T cell epitopes and antibody contact regions, possibly due to the small and poorly inducible reservoir that may be insufficient to drive effective viral escape in ECs. About 15% of ECs harbored nef deletions in intact proviruses, consistent with increased viral vulnerability to host immunity in the setting of nef dysfunction. Together, these results suggest a distinct signature of immune footprints in proviral sequences from ECs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据